Arca
Skip to content
Tools
Tools

Pruritis

Drug research and approvals for pruritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 59 studies of pruritis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 16 drug trials for it since 2013.

  • Recruiting worldwide: 59
  • Trials authorized in Canada: 16
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 59 recruiting on ClinicalTrials.gov ↗

How its trials ended

304 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 68 whose ending is known, 49% met their primary endpoint, 7% missed it and 44% stopped early.

  • Completed, result not reported16053%
  • Ongoing4414%
  • Met its primary endpoint3311%
  • Status unknown3211%
  • Stopped: other or unclear176%
  • Missed its primary endpoint52%
  • Stopped: enrollment or feasibility52%
  • Stopped: lack of efficacy31%
  • Stopped: sponsor or business decision31%
  • Stopped: safety1<1%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 16; search them all in Canada trials
Jul 9, 2026A 52-week multi-center, randomized, double-blind, placebo controlled phase 3 study to evaluate the efficacy, safety and tolerability of remibrutinib in adult…Remibrutinib (LOU064)Novartis PharmaceuticalsPending
Jul 9, 2026A 52-week multi-center, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy, safety and tolerability of remibrutinib in adult…Remibrutinib (LOU064)Novartis PharmaceuticalsPending
Mar 9, 2026An exploratory proof of concept study to assess the pharmacokinetics/pharmacodynamics of nemolizumab (CD14152) in adult participants with chronic pruritus of…Nemolizumab (CD14152)Galderma Canada IncClosed
Feb 27, 2026Incidence of pruritus using intrathecal fentanyl versus epidural fentanyl to initiate labour analgesiaFentanylDr. Valérie ZaphiratosPending
Oct 25, 2024A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus…DupixentSanofi-Aventis Canada IncOngoing
Sep 13, 2023A multicenter, randomized, double-blind, placebo-controlled 12-week study to evaluate the pharmacokinetics, pharmacodynamics, and safety of oral difelikefalin…DifelikefalinCara TherapeuticsClosed
Dec 7, 2021¿master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in…Dupilumab (SAR231893/REGN668)Sanofi-Aventis Canada IncOngoing
Nov 9, 2021Dialysis symptom control-pruritus outcome trial (disco-pot): a randomized blinded placebo controlled crossover trialNabiloneUniversity of ManitobaClosed
Dec 16, 2020A randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of oral difelikefalin (CR845) for moderate to severe…Difelikefalin (CR845)Cara TherapeuticsClosed
May 15, 2020Long-term safety and tolerability study of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis.Linerixibat (GSK2330672)GSKClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.